Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: The vasculogenic mimicry related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma

Fig. 6

Molecular docking pose. Screening of candidate small molecules for target proteins using molecular docking. The figure shows the docking poses of the CDH5 active pocket with Crassifogenin C (A), Episappanol (B), Gnetuhainin D (C), and Sappanone B (D). the MAPK1 active pocket with Isolappaol C (E), Leonoside F (F), Licorice Glycoside B (G), and Littorachalcone (H) in docking poses.MMP9 active pocket with Olivacine (I), Picrasidine I (J), Sagecoumarin (K), and Thalifaretine (L) in docking poses.MMP13 active pocket with Andalasin A (M), Dracunculifoside B (N), Glansreginin B (O) and Monocaffeyltartaric Acid (P) in docking poses

Back to article page